Jonathan Shannon

ORCID: 0009-0002-8275-6268
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Asymmetric Synthesis and Catalysis
  • Chemical Synthesis and Analysis
  • Asymmetric Hydrogenation and Catalysis
  • Catalytic Cross-Coupling Reactions
  • Crystallization and Solubility Studies
  • Coordination Chemistry and Organometallics
  • Synthesis and Catalytic Reactions
  • X-ray Diffraction in Crystallography
  • Advanced Synthetic Organic Chemistry
  • Synthesis and biological activity
  • Synthesis and Biological Evaluation
  • Melanoma and MAPK Pathways
  • Protein Degradation and Inhibitors
  • Antifungal resistance and susceptibility
  • Sulfur-Based Synthesis Techniques
  • Prostate Cancer Treatment and Research
  • Phytochemical compounds biological activities
  • Cancer-related gene regulation
  • Nail Diseases and Treatments
  • Ubiquitin and proteasome pathways
  • Organic and Inorganic Chemical Reactions
  • PI3K/AKT/mTOR signaling in cancer
  • Antimicrobial agents and applications
  • Chemical Synthesis and Reactions
  • Carbohydrate Chemistry and Synthesis

University College London
2014-2017

Transnational Press London
2014-2016

University of Nottingham
2007-2010

Bayer (Germany)
2009

Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of (AR-SV). Inhibitors transcriptional coactivators that regulate activity, the paralog histone acetyltransferase proteins p300 and CBP, are attractive therapeutic targets for lethal cancer. Herein, we validate targeting p300/CBP as a strategy describe CCS1477, novel small-molecule inhibitor conserved bromodomain. We...

10.1158/2159-8290.cd-20-0751 article EN Cancer Discovery 2021-01-11

The profile of PC945, a novel triazole antifungal designed for administration via inhalation, was assessed in range vitro and vivo studies. PC945 characterized as potent, tightly binding inhibitor Aspergillus fumigatus sterol 14α-demethylase (CYP51A CYP51B) activity (50% inhibitory concentrations [IC50s], 0.23 μM 0.22 μM, respectively) with characteristic type II azole spectra. Against 96 clinically isolated A. strains, the MIC values ranged from 0.032 to >8 μg/ml, while those voriconazole...

10.1128/aac.02280-16 article EN cc-by Antimicrobial Agents and Chemotherapy 2017-02-22

Aberrant activation of the MAPK pathway drives cell proliferation in multiple cancers. Inhibitors BRAF and MEK kinases are approved for treatment mutant melanoma, but resistance frequently emerges, often mediated by increased signaling through ERK1/2. Here, we describe fragment-based generation ERK1/2 inhibitors that block catalytic phosphorylation downstream substrates such as RSK also modulate without directly inhibiting MEK. X-ray crystallographic biophysical fragment screening followed...

10.1021/acs.jmedchem.8b00421 article EN Journal of Medicinal Chemistry 2018-05-18

Addition of AlMe3 to commercial THF solutions RZnX (R = aryl, functionalised vinyl; X Br, I) simultaneously promotes Schlenk equilibria (leading competent nucleophiles) and the formation an Al–Zn-ligand catalyst delivering 80–90% ee for Ar1CH(OH)Ar2 from aldehydes.

10.1039/b710681e article EN Chemical Communications 2007-01-01

ABSTRACT The antifungal effects of the novel triazole PC1244, designed for topical or inhaled administration, against Aspergillus fumigatus were tested in a range vitro and vivo studies. PC1244 demonstrated potent activities clinical A. isolates ( n = 96) with MIC 0.016 to 0.25 μg/ml, whereas voriconazole was 0.5 μg/ml. strong tight-binding inhibitor recombinant CYP51A CYP51B (sterol 14α-demethylase) enzymes strongly inhibited ergosterol synthesis 50% inhibitory concentration 8 nM. effective...

10.1128/aac.01941-17 article EN cc-by Antimicrobial Agents and Chemotherapy 2018-02-09

The presence of promoted Schlenk equilibria for organozinc halide species has been explicitly demonstrated by 13C NMR studies. Thus, addition methylaluminoxane (MeAlO)n, MAO, to RZnX (R=Et, Bn, ArCH2, (CH2)3CO2Et; X=Cl, Br) leads the formation ZnR2 and ZnX2MAO. For EtZnCl, equilibration ZnEt2 ZnX2MAO is rapid at -35 degrees C; a K value 0.19 M-1 indicates equilibrium favours (0.75-3.0 equiv MAO). Use RZnX/MAO mixtures allows copper-catalysed 1,4-addition 2-cyclohexenone be achieved, but...

10.1002/chem.200601739 article EN Chemistry - A European Journal 2007-02-07

Abstract A practical asymmetric 1,2‐addition of functionalised arylzinc halides to aromatic and aliphatic aldehydes is described by the use aminoalcohol catalysis in presence AlMe 3 . The process simple carry out, uses only commercially available reagents/ligands provides moderate good (80–96 % ee ) enantioselectivities for a wide range substrates. Either commercial ArZnX reagents or those prepared situ from low cost aryl bromides can be used. In latter case electrophilic functional groups...

10.1002/chem.200901803 article EN Chemistry - A European Journal 2009-11-24

11590 Background: Targeted degradation of androgen receptor (AR) and AR variants (ARV) remains an attractive therapeutic opportunity for patients with castrate resistant prostate cancer (CRPC). E1A binding protein (p300) CREB (CBP) are two closely related transcriptional activators AR. We have developed CCS1477 which is a potent, selective orally active small molecule inhibitor the bromodomain p300/CBP investigated its role in regulating expression function. Methods: Binding to p300, CBP...

10.1200/jco.2017.35.15_suppl.11590 article EN Journal of Clinical Oncology 2017-05-20

Aberrant activation of the mitogen-activated protein kinase pathway frequently drives tumor growth, and ERK1/2 kinases are positioned at a key node in this pathway, making them important targets for therapeutic intervention. Recently, number inhibitors have been advanced to investigational clinical trials patients with activating mutations B-Raf proto-oncogene or Ras. Here, we describe discovery candidate ASTX029 (15) through structure-guided optimization our previously published...

10.1021/acs.jmedchem.1c00905 article EN Journal of Medicinal Chemistry 2021-08-13

Aberrant activation of NLRP3 due to persistent tissue damage, misfolded proteins or crystal deposits has been linked multiple chronic inflammatory disorders such as cryopyrin-associated periodic syndrome (CAPS), neurodegenerative diseases, gouty arthritis, and numerous others. Hence, there an increasing interest in inhibitors therapeutics. A first generation bearing a sulfonylurea core MCC950 (developed by Pfizer) were discovered phenotypic screening, however their mode action was only...

10.1021/acs.jmedchem.4c01376 article EN Journal of Medicinal Chemistry 2024-11-25

A reductive conjugate addition nitro-Mannich reaction controls diastereoselectivity in a rapid entry to diverse array of 1,2,3,4-tetrahydroquinoxalines high yield.

10.1039/c6ob01530a article EN Organic & Biomolecular Chemistry 2016-01-01

A conjugate addition nitro-Mannich reaction followed by nitro reduction and intramolecular N-arylation gives diastereomerically pure substituted 1,2-diamine containing indolines. Placing the cyclisation handle on imine precursor derived from an ortho-bromine aromatic aldehyde gave corresponding β-nitroamines in 55-72% yields as single diastereoisomers. Nitro was effected with modified quantities of Zn/HCl a subsequent Pd(0) catalysed Buchwald Hartwig indoline products 40-70%

10.1039/c4ob01793e article EN cc-by Organic & Biomolecular Chemistry 2014-10-20

Conjugate additions of [Zn(bpy*)Cl(Et)] (bpy* = 4,4'-di- tert -butyl-2,2'-bipyridine) to cyclohex-2-en-1-one are promoted by ZnMe 2 in 88% ee but moderate yield under Cu I phosphoramidite catalysis. In the absence is inactive indicating a Schlenk-type equilibrium. Other derivatives [Zn(bpy*)Cl(R)] (R Bu, 4-methylbenzyl), prepared situ from [ZnCl(R)] and bipyridine give low yields due competing chloride abstraction. 13 C NMR studies indicate facile organo-ligand exchange between [Zn(bpy*)(Et)...

10.1135/cccc20071107 article EN Collection of Czechoslovak Chemical Communications 2007-01-01

Deprotonation of secondary alkane nitriles with nBuLi and addition to aryl imines gives kinetic anti-β-aminonitriles. Use LHMDS allows reversible protonation the reaction intermediate give syn-β-aminonitriles. The pure diastereosiomers can be isolated in good yields, mechanism was elucidated.

10.1021/acs.orglett.7b00679 article EN Organic Letters 2017-03-21

The base-promoted 1,2-addition of alkyl phenylsulfones to N-(para-methoxyphenyl) imines was investigated as a direct route stereochemically defined β-aminosulfones. Using nBuLi base, 2-(phenylsulfonyl)ethylbenzene added range give β-aminosulfone products in high yields single anti-diastereoisomers. Other less substituted were not successful.

10.1016/j.tetlet.2014.11.017 article EN cc-by Tetrahedron Letters 2014-11-10

Abstract Sulfone substituents are found to influence the diastereoselectivity of 1,2‐addition reaction imines (II).

10.1002/chin.201517113 article EN ChemInform 2015-04-01

Abstract ChemInform is a weekly Abstracting Service, delivering concise information at glance that was extracted from about 100 leading journals. To access of an article which published elsewhere, please select “Full Text” option. The original trackable via the “References”

10.1002/chin.201021050 article EN ChemInform 2010-04-29

Abstract ChemInform is a weekly Abstracting Service, delivering concise information at glance that was extracted from about 200 leading journals. To access of an article which published elsewhere, please select “Full Text” option. The original trackable via the “References”

10.1002/chin.200802048 article EN ChemInform 2007-12-20

Abstract ChemInform is a weekly Abstracting Service, delivering concise information at glance that was extracted from about 200 leading journals. To access of an article which published elsewhere, please select “Full Text” option. The original trackable via the “References”

10.1002/chin.200806087 article EN ChemInform 2008-01-23
Coming Soon ...